Sanofi’s (SNY) Buy Rating Reiterated at Argus
“The company also has a strong new drug pipeline that includes Toujeo, a next-generation insulin product, and dipilumab, for atopic dermatitis and other inflammatory conditions,” the analyst said.See also: Where Does Zika Virus Vaccine Research Stand Now? FY18 ExpectationsArgus expects the company’s 2017 revenues from continuing operations to benefit from the recent acquisition of Boehringer Ingelheim’s consumer health business and higher sales of multiple sclerosis products. At the same time, the firm expects reduced diabetes drug sales.The firm also sees margin pressure due to pricing pressures for diabetes products in the U.S. and costs related to the launch of Dupixent and Kevzara, partly offset by a sales force reorganization and other cost-savings initiatives.”In 2018, we expect continued solid demand for multiple sclerosis drugs and increased sales in emerging markets to outweigh weaker sales of diabetes drugs, and look for the company’s cost-savings program to benefit margins,,” Argus’ analyst commented.
A number of other research firms also recently weighed in on SNY. BidaskClub downgraded Sanofi from a buy rating to a hold rating in a research report on Friday, June 9th. Zacks Investment Research upgraded Sanofi from a hold rating to a buy rating and set a $55.00 target price for the company in a research report on Friday, June 2nd. HSBC Holdings plc upgraded Sanofi from a reduce rating to a hold rating in a research report on Wednesday, August 30th. Berenberg Bank downgraded Sanofi from a buy rating to a hold rating in a research report on Thursday, May 11th. Finally, Cowen and Company reiterated a market perform rating and set a $52.00 target price (up from $46.00) on shares of Sanofi in a research report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and five have assigned a buy rating to the company. The stock has an average rating of Hold and an average price target of $54.00.
Sanofi (SNY) opened at 49.31 on Friday. The company has a 50-day moving average price of $48.03 and a 200-day moving average price of $46.94. Sanofi has a 12-month low of $36.81 and a 12-month high of $50.24. The firm has a market cap of $123.84 billion, a P/E ratio of 11.75 and a beta of 0.88.
Sanofi (NYSE:SNY) last released its earnings results on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.74. The firm had revenue of $8.66 billion during the quarter, compared to the consensus estimate of $8.71 billion. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. Sanofi’s revenue was down 2.3% on a year-over-year basis. On average, analysts predict that Sanofi will post $3.30 earnings per share for the current year.
In other Sanofi news, major shareholder Sanofi acquired 60,595 shares of the company’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was acquired at an average cost of $478.98 per share, for a total transaction of $29,023,793.10. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.00% of the stock is owned by corporate insiders.
Several hedge funds have recently made changes to their positions in SNY. Harbour Capital Advisors LLC bought a new stake in shares of Sanofi during the 1st quarter worth $113,000. Parallel Advisors LLC lifted its position in shares of Sanofi by 42.5% during the 2nd quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock worth $139,000 after buying an additional 875 shares during the last quarter. YorkBridge Wealth Partners LLC lifted its position in shares of Sanofi by 33.7% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock worth $147,000 after buying an additional 776 shares during the last quarter. Eagle Ridge Investment Management bought a new stake in shares of Sanofi during the 2nd quarter worth $160,000. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its position in shares of Sanofi by 6,188.3% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock worth $171,000 after buying an additional 3,713 shares during the last quarter. Institutional investors and hedge funds own 9.33% of the company’s stock.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.